14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
REGN vs GNPX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.2); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs GNPX. Trailing 12-month operating profitability (REGN 30.4% vs GNPX 0.0%) and valuation multiples (REGN 14.8x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ REGN vs GNPX Key Questions & Quantitative Answers
As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.2); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, REGN generates $16.9B in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.
REGN screens cheaper on headline valuation multiples. REGN trades at 14.8x Forward P/E, 20.4x Trailing P/E, 1.15x PEG, and 5.6x EV/Revenue (21.5% FCF margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus GNPX (-233.7% ROE) capital efficiency.
In options market volatility and institutional positioning, REGN carries 39.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 55% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.